Specific to both intact and castrated treated groups, EZH2 inhibition alone did not provide anti-tumor efficacy, whereas response to PI3K/mTORC1 inhibition alone provided significant anti-tumor effect against intact tumors, but acquired resistance was noted in castrated conditions (Fig. 3D). The gene discussed is EZH2; the disease is neoplasm.